Literature DB >> 17577927

Expansion of normal and leukemic human hematopoietic stem/progenitor cells requires rac-mediated interaction with stromal cells.

Marjan Rozenveld-Geugien1, Inge O Baas, Djoke van Gosliga, Edo Vellenga, Jan Jacob Schuringa.   

Abstract

OBJECTIVE: To determine the involvement of Rac signaling in self-renewal and expansion on bone marrow stroma of normal CD34+ cells vs leukemic CD34+ cells from acute myeloid leukemia (AML) patients.
MATERIALS AND METHODS: Rac signaling was modulated by retroviral introduction of Racl-N17, Racl-V12, or by using the Rac inhibitor NSC23766. In long-term MS5 cocultures (leukemic) expansion, migration, adhesion, and presence of stem/progenitor cells were monitored in both normal as well as leukemic CD34+ cells.
RESULTS: Inhibition of Rac signaling impaired migration and adhesion of cord blood (CB) CD34+ cells on MS5 stroma. Long-term inhibition of Rac during a 5-week coculture period on stroma prevented association of hematopoietic progenitors with the bone marrow stromal cells and resulted in a dramatic decrease in the primitive stem cell frequency (long-term culture-initiating cell) in a dose-dependent manner. Many of these phenotypes were reversed in the presence of activated Racl-V12, including improved migration toward, and association with, MS5 cells. CD34+ AML cells were characterized by elevated levels of Rac activity (five of seven patients) and enhanced migration and adhesion to MS5 bone marrow stroma as compared to CB CD34+ cells. A dramatic decrease was observed in the formation of leukemic cobblestone area-forming cells as well as strongly diminished clonal expansion in the presence of the Rac inhibitor NSC23766.
CONCLUSION: Our data indicate that Rac signal transduction is required for the maintenance and expansion of both normal as well as leukemic stem/progenitor cells by mediating their interaction with stromal cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17577927     DOI: 10.1016/j.exphem.2007.02.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

Review 1.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

2.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

Authors:  Benjamin Mizukawa; Junping Wei; Mahesh Shrestha; Mark Wunderlich; Fu-Sheng Chou; Andrea Griesinger; Chad E Harris; Ashish R Kumar; Yi Zheng; David A Williams; James C Mulloy
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

3.  Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.

Authors:  Alison E Meyer; Cary Stelloh; Kirthi Pulakanti; Robert Burns; Joseph B Fisher; Katelyn E Heimbruch; Sergey Tarima; Quinlan Furumo; John Brennan; Yongwei Zheng; Aaron D Viny; George S Vassiliou; Sridhar Rao
Journal:  Leukemia       Date:  2022-07-01       Impact factor: 12.883

4.  Rac guanosine triphosphatases represent a potential target in AML.

Authors:  L U W Müller; R J Schore; Y Zheng; E K Thomas; M-O Kim; J A Cancelas; Y Gu; D A Williams
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

Review 5.  Rho GTPases in hematopoiesis and hemopathies.

Authors:  James C Mulloy; Jose A Cancelas; Marie-Dominique Filippi; Theodosia A Kalfa; Fukun Guo; Yi Zheng
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

6.  Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling.

Authors:  James C Mulloy; Mark Wunderlich; Yi Zheng; Junping Wei
Journal:  Cell Cycle       Date:  2008-11-08       Impact factor: 4.534

7.  Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2.

Authors:  Marta E Capala; Henny Maat; Francesco Bonardi; Vincent van den Boom; Jeroen Kuipers; Edo Vellenga; Ben N G Giepmans; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

8.  ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.

Authors:  Marta E Capala; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

9.  ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.

Authors:  Carolina Yaeko Namasu; Christiane Katzerke; Daniela Bräuer-Hartmann; Alexander Arthur Wurm; Dennis Gerloff; Jens-Uwe Hartmann; Sebastian Schwind; Carsten Müller-Tidow; Nadja Hilger; Stephan Fricke; Maximilian Christopeit; Dietger Niederwieser; Gerhard Behre
Journal:  Oncotarget       Date:  2017-10-26

10.  Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines.

Authors:  Natalia Fernández; Pablo Lorenzano Menna; Maia Cabrera; Emiliana Echeverria; Federico Remes Lenicov; Georgina Cardama; Nazareno Gonzalez; Carlos Davio
Journal:  Oncotarget       Date:  2017-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.